American Society for Pharmacy Law
ROUNDTABLE DISCUSSIONS
Join us for thought-provoking discussions with your fellow ASPL members, the 3rd Wednesday of each month. Registration is complimentary to all ASPL members.
Wednesday, May 25, 2022
12:00 – 1:00 pm Central
PBM and Drug Management Update for Commercial Plan
Pharmacy Benefit Managers (PBMs) are experiencing rapid changes post-Rutledge vs. PCMA. In this roundtable, we'll review briefly some of the newer states providing laws for PBMs in 2022, update any changes at the federal level, and then discuss overall trends in drug management, both in the pharmacy benefit drugs as well as medical benefit (J code) drugs. This lively session will host different industry subject matter experts and their points of view. No CE will be provided in this session. Bring your questions for this lively discussion with 3 different industry experts.
Speakers: Eric Barker, True Rx Health Strategies
Natalia Mazina - Mazina Law Rx Healthcare Law
Moderated by ASPL President Erin Albert - Apex Benefits
Wednesday, June 8, 2022
12:00 – 1:00 pm Central
An Overview of Changes to Claw Backs in CMS’ Part D Final Rule
For years the Centers for Medicare and Medicaid Services (CMS) has been considering ways to reform the use of pharmacy Direct and Indirect Remuneration (aka pharmacy DIR) in the Medicare Part D program. This spring CMS took highly anticipated action on DIR reform with its finalization of Medicare Advantage and Part D Final Rule for Contract Year 2024, which requires Part D plans to include certain kinds of pharmacy DIR (colloquially known as “claw backs”) in a pharmacy’s negotiated price at the point of sale. According to CMS, the rule is a win for patients who will see lower out-of-pocket costs at the pharmacy to the tune of $26.5 billion between 2024 and 2032. Some pharmacy advocates also claim the final rule is an important step to bring transparency to pharmacy negotiated prices. This presentation will give a historical overview of CMS’ actions on pharmacy DIR over the past 10 years. This presentation will then analyze CMS’ final rule and apply the analysis through the lens of pharmacies, payers/PBMs, and pharmaceutical manufacturers.
Speakers: Kala Shankle & Alan Arville, Epstein Becker Green Law
|
